BenevolentAI announces agreement with leading healthcare company to leverage BenevolentAI’s technology platform

BenevolentAI have collaborated with Novartis Global Drug Development on an initial project in oncology, which will see the application of our AI and machine learning technology to stratify patients and gain a better understanding of patient and disease heterogeneity to more precisely target medicines for patients who need them

Read More
BenevolentAI Awarded Technology Pioneer Status by World Economic Forum

Every year, the World Economic Forum welcomes leading early-stage technology companies from around the world into its Technology Pioneer’s community. In its own words, these companies are “poised to have a significant impact on business and society”. Today we are delighted and humbled to be named as one such Technology Pioneer.

Read More
BenevolentAI raises $115 million to extend its leading global position in the field of AI enabled drug development

BenevolentAI raises $115 million, now valued at $2 billion. Funds raised to significantly scale BenevolentAI drug development activities, broaden the disease areas on which it focuses, and extend its AI platform capabilities

Read More